Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0214 | 0.0271 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0558 | 0.077 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.1001 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.4177 | 0.4525 |
Brugia malayi | hypothetical protein | 0.0025 | 0.1001 | 0.1001 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.1001 | 0.5 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Schistosoma mansoni | zinc finger protein | 0.0019 | 0.0024 | 0.003 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.1001 | 0.5 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0059 | 0.7246 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0035 | 0.2968 | 0.4096 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.007 | 0.923 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.1001 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.1001 | 0.5 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0558 | 0.0707 |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0019 | 0 | 0.5 |
Echinococcus multilocularis | zinc finger protein | 0.0019 | 0.0024 | 0.0033 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0035 | 0.2968 | 0.4096 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.3833 | 0.4153 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0059 | 0.7246 | 1 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.1001 | 0.5 |
Schistosoma mansoni | bromodomain containing protein | 0.0062 | 0.7891 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0.1001 | 0.5 |
Brugia malayi | Bromodomain containing protein | 0.0038 | 0.3394 | 0.3394 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Echinococcus granulosus | zinc finger protein | 0.0019 | 0.0024 | 0.0033 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.1001 | 0.1085 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0558 | 0.077 |
Loa Loa (eye worm) | PHD-finger family protein | 0.002 | 0.0214 | 0.0232 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Brugia malayi | PHD-finger family protein | 0.0025 | 0.0984 | 0.0984 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.1001 | 0.5 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.3407 | 0.3691 |
Onchocerca volvulus | 0.0019 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 1 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 1 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 9.59 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 9.63 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 9.73 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 96 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 0.75 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 0 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 1 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 1 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 96 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 6.09 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.80981 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.